coumarin
Coumarin itself was first isolated from the tonka bean Coumarouna odorata. Coumarin and its derivatives are alpha-benzopyrones. Coumarin is metabolized in humans to 7-hydroxycoumarin. Coumarin is a secondary phytochemical with hepatotoxic and carcinogenic properties. For the carcinogenic effect, a genotoxic mechanism was considered possible. Coumarins have a significant effect on physiological, bacteriostatic and anti-tumor activity. Coumarins have potent edema protective function and thus involved in the treatment of lymphedema, elephantiasis and other high protein edema conditions. Coumarin has appetite-suppressing properties. — NCATS
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2002 (NCT00264277)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
Coumarin induces proteolysis of high-molecular-weight proteins present in lymphedema. Small-size protein fragments can then be more easily drained via the lymphatics. The oncotic pressure drops and edema lessens.
Chemistry & pharmacology
SMILES
O=C1OC2=C(C=CC=C2)C=C1- Mol. weight
- 146.1427 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCoumarin ↗
- NCATSA4VZ22K1WT ↗
- ChEMBLCHEMBL6466 ↗
- ChEMBLCHEMBL278172 ↗
Also known as
- 1,2-benzopyrone
- 1,2-benzopyrone
- 1,2-benzopyrone
- 1,2-benzopyrone
- 2-chromenone
- 2h-1-benzopyran-2-one
- 2h-1-benzopyran-2-one
- 2h-benzo(b)pyran-2-one
- 2h-benzo(b)pyran-2-one
- 5,6-benzo-alpha-pyrone
- coumarin
- coumarin
- coumarin
- coumarin
- coumarin
- coumarin
- coumarin
- coumarin
- coumarin
- coumarinic lactone
- coumarinic lactone
- cumarin
- cumarin
- cumarin
- dipteryx
- lodema
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06951191 | Phase 4 | Jun 23, 2025 | University of Missouri |
| NCT01848210 | Phase 4 | May 1, 2013 | Takeda |
| NCT00264277 | Phase 4 | Sep 1, 2002 | University of Bologna |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 1 | 1 | 1 | 2013 |
| University of Bologna | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Missouri | Academic/Hospital | 1 | 1 | 1 | 2025 |